<DOC>
	<DOCNO>NCT02038920</DOCNO>
	<brief_summary>This study phase 3 , multicenter , randomize , double-blinded , placebo-controlled , parallel-group study examine efficacy , safety , pharmacokinetics MLN0002 ( Vedolizumab ) induction maintenance therapy Japanese patient moderately severely active Crohn 's disease .</brief_summary>
	<brief_title>Phase III Study MLN0002 ( 300 mg ) Treatment Crohn 's Disease</brief_title>
	<detailed_description>This phase 3 , multicenter , randomize , double-blinded , placebo-controlled , parallel-group study examine efficacy , safety , pharmacokinetics intravenous Vedolizumab ( 300 mg ) infusion induction maintenance therapy Japanese patient moderately severely active Crohn 's disease .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Vedolizumab</mesh_term>
	<criteria>1 . Patients age 15 80 year ( inclusive ) time consent 2 . Patients diagnosis smallintestinal , largeintestinal , small/largeintestinal Crohn 's disease establish base Revised Diagnostic Criteria Crohn 's disease issue Research Group Intractable Inflammatory Bowel Disease Designated Specified Disease Ministry Health , Labor Welfare Japan ( 2012 ) least 3 month start administration study drug 3 . Patients baseline Crohn 's Disease Activity Index ( CDAI ) score 220 450 ( inclusive ) meeting least one following : Creactive protein ( CRP ) screen test 0.30 mg/dL Patients irregular semicircular ulcer multiple aphthae ( 10 ) observe extensive area small large intestine endoscopy image test within 4 month start administration study drug Patients longitudinal ulcer cobblestone appearance observe small large intestine endoscopy image test within 4 month start administration study drug 4 . In case patient meet following criterion ; patient ≥ 8year history extensive limited colitis , patient age ≥ 50 year , patient firstdegree family history colon cancer , complication colon cancer dysplasia rule total colonoscopy start study drug administration ( Or result total colonoscopy perform within 1 year give consent available ) 5 . Patients meet criterion treatment failure least one follow agent receive within previous 5 year period give consent Corticosteroids Resistance Dependence Intolerance Immunomodulators ( azathioprine , 6mercaptopurine methotrexate ) Refractory Intolerance AntiTNFα antibody Inadequate response Loss response Intolerance Patients evidence suspect abdominal abscess 2 . Patients history subtotal total colectomy 3 . Patients resection small intestine least 3 location diagnosis short bowel syndrome 4 . Patients ileostomy , colostomy , internal fistula , severe intestinal stenosis 5 . Patients start 5aminosalicylic acid oral drug probiotic treatment , antimicrobial treat Crohn 's disease , 30 mg/day less oral corticosteroid within 13 day initiation study drug administration . If drug use within 14 day initiation study drug administration , dosage must change use discontinue within 13 day initiation study drug administration 6 . Patients receive 5aminosalicylic acid corticosteroid enemas/suppositories , intravenous corticosteroid injection , 30 mg/day oral corticosteroid , medication diarrheapredominant irritable bowel syndrome , Chinese herbal medicine treatment Crohn 's disease ( e.g. , Daikenchuto ) within 13 day initiation study drug administration 7 . Patients receive azathioprine , 6mercaptopurine , methotrexate within 27 day initiation study drug administration . However , shall apply patient receive drug 83 day initiation study drug administration continue steady dose administration drug 27 day initiation study drug administration 8 . Patients receive cyclosporin , tacrolimus , tofacitinib study drug treatment ulcerative colitis within 27 day initiation study drug administration 9 . Patients receive adalimumab within 27 day initiation study drug administration biological drug adalimumab within 55 day initiation study drug administration.Topical administration ( intraocular implantation treatment agerelated maculopacy ) allow 10 . Patients receive live vaccination within 27 day initiation study drug administration 11 . Patients undergone intestinal resection within 27 day initiation study drug administration anticipate require intestinal resection study 12 . Patients receive leukocytapheresis granulocyte apheresis within 27 day initiation study drug administration 13 . Patients receive intravenous hyperalimentation total enteral nutrition within 20 day initiation study drug administration . Or patient fast 14 . Patients receive enteral nutrition &gt; 900 kcal/day start enteral nutrition &lt; = 900 kcal/day within 20 day initiation study drug administration . Patients receive 900 kcal/day less enteral nutrition least 21 day initiation study drug administration dosage change medication discontinue within 20 day initiation study drug administration 15 . Patients evidence adenomatous colonic polyp need remove start study drug administration 16 . Patients history complication dysplasia small large intestine</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>